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Abstract
Background: The primary aim of treatment of a patient who has developed metastatic disease is palliation. The
objectives of the current study are to describe and quantify the clinical management of women with metastatic breast
cancer from the diagnosis of metastatic disease until death and to analyze differences between age groups.
Methods: Data were collected from the medical files of all patients (n = 116) who had died after December 31, 1999,
after a diagnosis of metastatic breast cancer in two teaching hospitals in the south of the Netherlands.
Results: Of the 116 patients included in our study, 10 (9%) already had metastatic disease at diagnosis and 106 developed
distant disease after the diagnosis of localized breast cancer. Before they died, 70% of the 116 patients developed
metastases in one or more bones, 50% in the lung and/or pleura, 50% in the abdominal viscera, 23% in the central nervous
system, and 19% in the skin. Patients younger than 50 years were much more likely to develop metastases in the central
nervous system than patients 50 years and older. Seventy-seven (66%) of the 116 patients with metastatic breast cancer
received chemotherapy. This proportion decreased with age (p = 0.005), as did the number of schemes per patient.
Together, they received 132 chemotherapy schemes, of which 35 (27%) resulted in partial remission or stabilization of
the disease process. Ninety-eight patients (84%) received hormonal treatment. This proportion did not differ between
the three age groups. Together, they received 216 hormonal treatments, 38 (16%) of which resulted in partial remission
or stabilization of the disease process. Seventy-nine patients (68%) received palliative radiotherapy. This proportion
decreased with age (p = 0.03). Together, they underwent 216 courses, 176 (77%) of which resulted in relief of the
complaints.
Conclusion: Patients aged 70 years and older are less likely to receive chemotherapy or radiotherapy. Part of this
difference could be explained by their shorter survival time after the diagnosis of metastatic disease and their lower risk
of developing brain and bone metastases. However, more research is needed to understand the age-related differences
in the treatment of metastatic breast cancer, and especially how comorbidity and frailty limit therapeutic choices.
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In most western countries the life-time breast cancer risk
is around 10%. About 20–40% of these patients will ulti-
mately develop metastatic disease and 4–10% of patients
will present with metastatic breast cancer (MBC) at diag-
nosis [1]. Once metastases are detected, the median sur-
vival time is about 24 months, with a range from several
months to many years, depending on the site of the
metastasis as well as the number of metastatic sites [2-5].
The primary aim of the treatment of a patient who has
developed metastatic disease is palliation.
The aims of the current study are to describe and quantify
the clinical management of women with metastatic breast
cancer, from the time of clinical diagnosis of distant dis-
ease until death, and to analyze the response to treatment
and overall survival. To determine how clinical manage-
ment and outcome vary with age, the analyses were per-
formed according to specific age groups.
Methods
Data collection
Patients were retrieved from the population-based Eind-
hoven Cancer Registry (ECR). Since 1989, the ECR has
recorded follow-up information on all patients with
breast cancer, including the date and site of loco-regional
and distant metastasis and the date of death. Information
on date of death was obtained from the municipal regis-
tries in the area of the Eindhoven Cancer Registry and the
Central Bureau for Genealogy. The latter is an institution
that collects data on all deceased Dutch citizens via the
municipal registries. In this way, information on patients
who had moved outside the registry area was also
obtained. Patients who died outside the Netherlands were
wrongly listed as 'alive'. However, the estimated propor-
tion of these patients was less then 0.3%. All 281 patients
with a history of breast cancer who died after December
31, 1999 and had been treated at the Catharina Hospital
in Eindhoven or the Máxima Medical Center in Veld-
hoven were selected for the study. These hospitals are
both non-academic, teaching hospitals. According to the
data of the ECR, 133 of these 281 patients developed dis-
tant metastases, including 11 patients with metastatic dis-
ease at the time of diagnosis of the primary tumor. It was
assumed that the remaining 148 patients did not die from
breast cancer; their mean age at death was 77 years. Five of
the 133 patients with metastatic disease had to be
excluded, because their medical records could not be
traced. Another 12 patients were excluded because their
metastases appeared to be related to another primary
tumor or were redefined as a locoregional recurrence after
review of their medical records. Thus, 116 patients
remained available for the study. For each of these 116
patients, detailed information was collected on the site(s)
of metastases, diagnostic procedures, treatment, hospital-
ization and clinical follow-up, starting from the time of
diagnosis of distant disease. The first site of metastatic dis-
ease and all subsequent sites were recorded separately. For
patients receiving systemic treatment, the type of drug and
the reason for any postponement or dose reduction were
recorded. Response to systemic treatment was measured
clinically, biochemically or by radiological imaging.
Assessment of treatment response was limited by the ret-
rospective nature of the study. Thus, when evaluating the
response to a new endocrine treatment or a new course of
chemotherapy, patients with stable disease or partial or
complete remission were taken together as one group and
considered as responders. In all other cases patients were
considered to have progressive disease. According to the
information in the medical records, the response to radi-
otherapy was judged to be positive if the patient reported
fewer complaints and negative if the severity of the com-
plaints had not changed or increased. Data on the primary
tumor and primary therapies were available from the
database of the ECR.
Our study was based on a review of clinical charts only
and hence needed no approval from our local ethics com-
mittee.
Statistical analysis
The date of first evidence of metastatic disease was defined
as the date of diagnosis. The metastasis-free interval was
defined as the interval between the date of diagnosis of
the primary tumor and the date of diagnosis of metastastic
disease, excluding the patients with metastatic disease at
the time of diagnosis of the primary tumor.
To study age-related differences in treatment, response to
treatment and survival patients were divided into three
age groups: <50 years (n = 34), 50–69 years (n = 62) and
70+ years (n = 20), using the age at initial diagnosis of
breast cancer.
The frequency distributions of the different variables
between the three age groups were compared by means of
the likelihood ratio Chi-square test or, when expected
counts were less than five, Fisher's Exact test. The Kruskal
Wallis test was used to compare continuous variables
between the three age groups. The interval from diagnosis
of the primary tumor until diagnosis of metastatic disease
and the interval from diagnosis of metastatic disease until
death found for the three age groups were compared by
the logrank test. The significance level was set at 0.05 for
all analyses.
Results
Patient and disease characteristics
Patient and disease characteristics are presented in Table
1. Of all 116 patients included in our study, 10 (9%)Page 2 of 8
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Table 1: Characteristics of primary tumor and metastatic disease according to age (%)
Characteristic Age at time of diagnosis of primary tumor
20–49 (n = 34) 50–69 (n = 62) 70+ (n = 20) p-value
No. (%) No. (%) No. (%)
Tumor size
T1 15 (44) 27 (43) 7 (35) 0.60
T2 16 (47) 25 (40) 7 (35)
T3 0 (0) 1 (2) 0 (0)
T4 3 (8) 8 (12) 6 (30)
Tx 0 (0) 1 (2) 0 (0)
Lymph node status
N+ 19 (55) 32 (51) 8 (40) 0.65
N- 11 (32) 21 (33) 6 (30)
Unknown 4 (11) 9 (14) 6 (30)
Metastasis
M0 31 (91) 55 (88) 19 (95) 0.91
M1 3 (8) 7 (11) 1 (5)
Histology
ductal 21 (61) 35 (56) 14 (70) 0.89
lobular or mixed 9 (25) 19 (29) 3 (20)
other 4 (11) 8 (12) 3 (10)
Primary therapy
surgery 33 (97) 59 (95) 19 (95) 1.00
radiotherapy 25 (73) 42 (67) 14 (70) 0.86
systemic therapy 21 (61) 36 (58) 14 (70) 0.64
other 0 (0) 1 (1) 0 (0) -
Metastatic disease
Interval (months) from diagnosis primary tumor until diagnosis of metastatic disease
Median (range) 25 (14–47) 42 (17–73) 23 (14–48.5) 0.07
Interval from diagnosis of metastatic disease until death
Median (range) 21 (11–45) 22 (9–50) 12 (6–31.5) 0.048
First site of metastatic disease
bone 14 (41) 18 (29) 5 (25) 0.21
lung and/or pleura 9 (26) 20 (32) 8 (40)
abdominal viscera 3 (8) 12 (19) 1 (5)
other 8 (23) 12 (19) 6 (30)
All metastatic sites (until death)
bone 27 (79) 43 (69) 11 (55) 0.16
lung and/or pleura 16 (47) 31 (50) 11 (55) 0.32
abdominal viscera 20 (58) 33 (53) 5 (25) 0.16
central nervous system 15 (44) 11 (17) 1 (5) 0.001
skin 6 (18) 12 (19) 5 (25) 0.80
other 9 (26) 14 (23) 4 (20) 0.88
Co-morbid conditions
Previous cancer 1 (3) 2 (3) 2 (10) 0.46
Lung disease* 5 (15) 8 (13) 5 (25) 0.45
Cardiovascular disease** 1 (3) 23 (37) 12 (60) <0.000
1
Diabetes 0 (0) 5 (8) 7 (35) 0.0002
* Asthma/COPD, pulmonary fibrosis
** Intermittent claudication, Myocardial infarction, CABG, Angina, Heart failure, CVA, TIA, Hypertension
BMC Cancer 2006, 6:179 http://www.biomedcentral.com/1471-2407/6/179already had metastatic disease at diagnosis and 106 devel-
oped distant disease after a diagnosis of localized breast
cancer with or without positive lymph nodes. The mean
age of the patients was 58 years (range: 21–88) at the time
of diagnosis of the primary tumor and 61.5 years (range:
23–93) at the time of diagnosis of metastatic disease (Fig-
ure). No significant differences were observed between
age groups as far as the size of the primary tumor, axillary
nodal status and the proportion of patients with meta-
static disease at the time of diagnosis of the primary tumor
were concerned. Also the proportion of patients undergo-
ing surgery, radiotherapy or systemic treatment as part of
their primary treatment did not differ between the three
age groups.
Among the patients without metastatic disease at diagno-
sis, the length of the metastasis-free interval tended to be
longer for patients 50–69 years than for younger and
older patients (p = 0.07).
Disease progression and survival
Before they died, 70% of the 116 patients developed
metastases in the bone, 50% in the lung and/or pleura,
50% in the abdominal viscera, 23% in the central nervous
system, and 19% in the skin (Table 1). Patients younger
than 50 years were much more likely to develop metas-
tases in the central nervous system than patients 50 years
and older. The risk of developing bone or visceral metas-
tases seemed to decrease with age (p = 0.16). The median
survival after the diagnosis of metastatic disease was 12
months for patients 70 years and older and 21 months for
patients younger than 70 years (p = 0.048).
Management of metastatic breast cancer
Table 2 shows the differences in the management of the
116 patients with metastatic breast cancer according to
age group. As far as diagnostic procedures are concerned,
the median numbers of laboratory tests and imaging pro-
cedures were significantly lower among patients aged 70
Table 2: Management of patients with metastatic breast cancer, according to age group
age at time of diagnosis of primary tumor
20–49 (n = 34) 50–69 (n = 62) 70+ (n = 20) p-value
Diagnostic procedures
Laboratory tests:
No. of patients 34 (100%) 61 (98%) 18 (90%) 0.06
No. of tests per patient* 45 (26–68) 35 (20–58) 13 (8–33) 0.005
Imaging:
No. of patients 33 (97%) 62 (100%) 19 (95%) 0.09
No. of exams per patient* 17 (13–32) 16.5 (9–26) 7 (4–19) 0.009
Histological or cytological confirmation:
No. of patients 20 (58%) 37 (59%) 10 (50%) 0.69
Hospital admission
No. of patients 31 (91%) 56 (90%) 15 (75%) 0.15
No. of admissions (median) * 4 (2–5) 3 (2–4) 2 (1–4) 0.06
Mean duration per admission (days) * 8.5 (5–10) 12 (6.5–17) 12 (4.6–16) 0.02
Reason for hospital admission:
Treatment (surgery, radiotherapy, systemic) 22 (65%) 35 (56%) 3 (15%) 0.001
Treatment-related complications 10 (29%) 9 (15%) 1 (5%) 0.05
Disease progression 30 (88%) 49 (79%) 14 (70%) 0.25
Disease progression and treatment-related complications 8 (24%) 15 (24%) 3 (15%) 0.68
Not related to breast cancer 0 (0%) 11 (18%) 3 (15%) 0.03
Visits to medical oncologist
No. of patients (%) 34 (100%) 61 (98%) 17 (85%) 0.007
No of visits per patient* 25 (14–42) 19 (8–32) 9 (7–18) 0.02
Treatment
Chemotherapy:
No. of patients 27 (79%) 35 (56%) 5 (25%) 0.005
Hormonal treatment:
No. of patients 28 (82%) 54 (87%) 16 (80%) 0.68
Radiotherapy:
No. of patients 27 (79%) 43 (69%) 9 (45%) 0.03
* median with 25% and 75% quartiles between parenthesesPage 4 of 8
(page number not for citation purposes)
BMC Cancer 2006, 6:179 http://www.biomedcentral.com/1471-2407/6/179years and older compared to the patients younger than 70
years of age. The proportion of patients visiting a medical
oncologist and the number of visits decreased with
increasing age. The large majority of the patients was
admitted to hospital at least once after the diagnosis of
metastatic disease. The median number of admissions was
3, being somewhat higher for patients younger than 50
years than for patients 70 years and older (p = 0.06). The
mean duration of admission was significantly longer for
patients 50 years and older than for younger patients (p =
0.02). Progression and treatment of metastatic disease
were the main reasons for hospital admission in all age
groups. Other important reasons for hospital admission
were the treatment of co-morbid conditions and the man-
agement of treatment-related complications. Of the 116
patients, 53 (46%) died in the hospital.
The proportion of patients with metastatic disease receiv-
ing chemotherapy decreased with age (Table 2), as did the
number of schemes (Table 3). Patients 20–49 and 50–69
years of age were treated mainly with combination chem-
otherapy (CAF, CMF or FEC), whereas patients 70 years
and older were treated with (less aggressive) mono-
therapy, such as mitoxantrone and vinorelbine. Treatment
delays occurred in about one-third of the cases, mainly
due to myelosuppression. Dose reductions were relatively
rare and in most cases they were a result of myelosuppres-
sion. Thirty-five of the 132 chemotherapy schemes (27%)
resulted in partial remission or stabilization of the disease
process. Complete remission was observed only once.
The proportion receiving hormonal treatment did not dif-
fer between the three age groups (Table 2). Tamoxifen and
aromatase inhibitors were usually given as first or second
line treatments and megestrol acetate was given to one-
third of the patients, mainly as a third-line drug (Table 4).
Thirty-eight of the 216 hormonal treatments (16%)
resulted in partial remission or stabilization of the disease
process.
Of the 116 patients, 79 received palliative radiotherapy.
The proportion decreased with age (Table 2). Together,
the 79 patients underwent 216 courses, of which 160
(70%) were less than 20 Gy and 176 (77%) resulted in a
relief of the complaints of the patient (Table 5).
Discussion
The current study gives an accurate picture of the clinical
management of women with metastatic breast cancer in
two general hospitals in the Netherlands. The care for
these patients is characterized by extensive laboratory test-
ing and diagnostic imaging and by intensive treatment,
associated with regular hospital admission. Furthermore,
frequent outpatient visits to the medical oncologist, sur-
geon, radiation oncologist and other disciplines involved
in the treatment of metastatic disease were required.
Substantial differences were observed between younger
and older patients with metastatic breast cancer as far as
their prognosis, the metastatic pattern and the manage-
ment of their disease are concerned. As has been con-
firmed by other studies [2,6,7], elderly patients had a
worse prognosis than their younger counterparts. They
also had a lower risk of developing bone, visceral and
brain metastases during the course of their disease, which
is in line with other studies [8-10]. One hypothesis, origi-
nating from studies among patients receiving paclitaxel
and trastuzumab, is that the central nervous system is an
important sanctuary site and that the higher risk of brain
metastases among younger patients is associated with bet-
ter systemic control of extracerebral metastases and a pro-
longed survival [11,12].
Patients aged 70 years and older were less likely to receive
chemotherapy or radiotherapy and underwent fewer stag-
ing procedures. Part of this difference can be explained by
their shorter survival time after diagnosis of metastases
and the fact that metastases to the bone and brain
occurred less frequently. A further explanation for the
decrease in the number of staging procedures with
increasing age is that the therapeutic consequences
become less relevant, especially in the case of (serious) co-
morbidity, which is present in about two-thirds of the
patients of 75 years and older [13].
As was confirmed by our findings, planning therapy is not
always straightforward for older patients because they are
more likely to present with co-morbidity and frailty which
limits the therapeutic choices [14]. Although only a few
elderly patients received chemotherapy in our study, it
was well-tolerated with no need for dose reductions.
Age distribution at time of diagnosis of primary tumor (PT) and at the time of diagnosis of metastatic disease (MD) (n = 116)Figure 1
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in overall good health are able to tolerate chemotherapy
as well as their younger counterparts [15]. However, there
is some evidence that although older patients do not differ
from their younger counterparts in their acceptance of
chemotherapy, they are less willing to trade survival for
current quality of life [16]. For the decision on the admin-
istration of chemotherapy to elderly patients, it is impor-
tant to identify the variables that influence their tolerance
to this treatment. Extermann and colleagues have
attempted to design a predictive risk score for elderly can-
cer patients, including patient-related and chemotherapy-
related variables that correlate independently with toxicity
[17]. Although the results of their pilot study should be
interpreted with care, diastolic blood pressure and bone
marrow invasion were found to be associated with toxic-
ity, in addition to the known toxicity of the different
chemotherapeutic regimens. As for adjuvant chemother-
apy, a comprehensive geriatric assessment may be a useful
tool to predict the risk of toxicity and/or the efficacy of sys-
temic treatment for elderly patients [18].
Our study has several limitations. First, when considering
the results it should be realized that the number of
patients was small and that the large number of tests for
possible associations carries the added risk that appar-
ently significant differences will occur by chance alone.
Second, our study is based on patients treated in two non-
academic, teaching hospitals and it is not sure that com-
parable results would have been obtained for patients
treated in an academic centers or in smaller non-teaching
hospitals. And third, the lack of information on hormone
receptor status is limiting the reconstruction of the deci-
sion-making process on the use of endocrine treatment.
Table 3: Palliative chemotherapy, according to age group
Chemotherapy Age at time of diagnosis of primary tumor
20–49 (n = 27) 50–69 (n = 35) 70+ (n = 5) total (n = 67)
Number of schemes
1 8 14 3 25
2 11 14 2 27
3 4 4 0 8
4 4 2 0 6
5 0 1 0 1
Total number of schemes 58 67 7 132
Drugs used
CAF 16 15 0 31
CMF 14 16 0 30
FEC 7 3 0 10
taxotere 9 7 0 16
mitoxantrone 1 8 3 12
vinorelbine 4 5 3 12
other 7 13 1 21
Reason for postponement
bone marrow suppression 4 11 1 16
fever 2 0 0 2
toxicity 2 6 0 8
infection 1 2 2 5
Doses
100% 52 57 7 116
80% 1 2 0 3
75% 3 5 0 8
70% 0 1 0 1
50% 1 2 0 3
Reason for dose reduction
bone marrow suppression 5 6 0 11
toxicity 1 2 0 3
other 1 3 0 4
Response
yes* 15 20 0 35
no (progressive disease) 43 46 5 91
*stable disease, partial or complete remissionPage 6 of 8
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ciated with the treatment of patients with metastatic
breast cancer. In a Canadian study of 75 patients the mean
total health care costs during the interval from diagnosis
of first recurrence or metastasis until death were estimated
at 36,474 Canadian Dollars in 1995 (25,686 Euros),
including homecare. Inpatients costs accounted for more
than 50% of the total costs in all age groups [19]. Another
study demonstrated the dependency of the costs on the
duration and the site of metastatic involvement [20]. In
1988, Holli and Hakama questioned the cost-effective-
ness of the treatment of metastatic breast cancer and sug-
gested that resources for diagnostic investigations and
treatment of this group could better be used to improve
quality of life and to conserve resources [21]. This opinion
was based on their observation that response is generally
poor and only rarely translates into detectable survival
advantages. However, for metastatic breast cancer, treat-
ment can be recommended even in the absence of survival
improvement, if it contributes to symptom control and,
consequently, the quality of life. Cost-utility analyses are
recommended to solve this issue [22]. At the same time, a
greater effort is needed to develop reliable predictors of
response to treatment for individual patients with meta-
static breast cancer in an effort to improve quality of life
and manage costs [23].
Conclusion
The treatment of patients with metastatic breast cancer is
changing rapidly and it is very likely that the agents used
in our study no longer represent current treatment. For
example, taxanes have rapidly become first-line therapy
and many new drugs, such as trastuzumab, have become
available; furthermore multiple agent therapy has been
given a more prominent place [24]. Although the agents
have altered, it is not likely that changes have taken place
in the considerations to start second or third line chemo-
therapy or endocrine treatment, and therefore the results
of the current retrospective study may serve as a reference
for the implementation and monitoring of new diagnostic
and therapeutic interventions and their cost-effectiveness.
However, more research is needed to understand the age-
related differences in the treatment of metastatic breast
cancer, and especially how co-morbidity and frailty limit
therapeutic choices. It should be realized that despite the
broadening of the therapeutic spectrum, quality of life
Table 4: Palliative hormone therapy, according to age group
Hormonal treatment Age at time of diagnosis of primary tumor
20–49 (n = 28) 50–69 (n = 54) 70+ (n = 16) total (n = 98)
Total number of courses 70 112 34 216
Drug
tamoxifen 27 35 8 70
aromatase inhibitor 21 40 11 72
megestrol acetate 13 24 8 45
other 9 13 7 29
Response
yes* 7 28 3 38
no (progressive disease) 63 82 31 176
*stable disease, partial or complete remission
Table 5: Palliative radiotherapy, according to age group
Radiotherapy Age at time of diagnosis of primary tumor
20–49 (n = 27) 50–69 (n = 43) 70+ (n = 9) total (n = 79)
Total number of courses 94 113 20 227
Dose intensity (Gy)
0–9 37 38 10 85
10–19 29 38 8 75
20–29 24 25 0 49
30+ 4 12 2 18
Response*
positive effect 72 89 15 176
no effect 20 24 5 49
*positive effect: patient reporting less complaints; no effect: patients reporting no change or increased severity of complaintsPage 7 of 8
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and symptom palliation remain the cornerstones of deci-
sion-making for women of all age groups with metastatic
breast cancer.
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